| Abstract
| - Novel 3-cyanoisoquinoline Kv1.5 antagonists have beenprepared and evaluated in in vitro and in vivo assays for inhibition ofthe Kv1.5 potassium channel and its associated cardiac potassiumcurrent, IKur. Structural modifications of isoquinolinone lead 1 affordedcompounds with excellent potency, selectivity, and oral bioavailability.
|
